A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation - PubMed
- ️Tue Jan 01 2008
Multicenter Study
. 2008 Nov 1;112(9):3574-81.
doi: 10.1182/blood-2008-02-140095. Epub 2008 Jul 7.
Myriam Labopin, Franco Aversa, Jakob M Rowe, Donald Bunjes, Philippe Lewalle, Arnon Nagler, Paolo Di Bartolomeo, João F Lacerda, Maria Teresa Lupo Stanghellini, Emmanuelle Polge, Francesco Frassoni, Massimo F Martelli, Vanderson Rocha; Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group
Affiliations
- PMID: 18606875
- DOI: 10.1182/blood-2008-02-140095
Free article
Multicenter Study
A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation
Fabio Ciceri et al. Blood. 2008.
Free article
Abstract
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an alternative treatment to patients with high-risk acute leukemia lacking a human leukocyte antigen-matched donor. We analyzed 173 adults with acute myeloid leukemia (AML) and 93 with acute lymphoblastic leukemia (ALL) who received a haplo-HSCT in Europe. All grafts were T cell-depleted peripheral blood progenitor cells from a direct family or other related donor. At transplantation, there were 25 patients with AML in CR1 (complete remission 1), 61 in more than or equal to CR2, and 87 in nonremission, and 24 with ALL in CR1, 37 in more than or equal to CR2, and 32 in nonremission. Median follow-up was 47 months in AML and 29 months in the ALL groups. Engraftment was observed in 91% of the patients. Leukemia-free survival at 2 years was 48% plus or minus 10%, 21% plus or minus 5%, and 1% for patients with AML undergoing transplantation in CR1, more than or equal to CR2, and nonremission, and 13% plus or minus 7%, 30% plus or minus 8%, and 7% plus or minus 5% in ALL patients, respectively. In conclusion, haplo-HSCT can be an alternative option for the treatment of high-risk acute leukemia patients in remission, lacking a human leukocyte antigen-matched donor.
Similar articles
-
Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, Huang H, Karakasis D, Koc Y, Michallet M, Picardi A, Sanz J, Santarone S, Sengelov H, Sierra J, Vincent L, Volt F, Nagler A, Gluckman E, Ciceri F, Rocha V, Mohty M; Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology working party-EBMT; ALWP-EBMT study. Ruggeri A, et al. Leukemia. 2015 Sep;29(9):1891-900. doi: 10.1038/leu.2015.98. Epub 2015 Apr 17. Leukemia. 2015. PMID: 25882700
-
Mo XD, Xu LP, Zhang XH, Liu DH, Wang Y, Chen H, Yan CH, Chen YH, Han W, Wang FR, Wang JZ, Liu KY, Huang XJ. Mo XD, et al. Int J Cancer. 2015 Apr 1;136(7):1697-707. doi: 10.1002/ijc.29146. Epub 2014 Sep 2. Int J Cancer. 2015. PMID: 25138425
-
TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients.
Kaynar L, Demir K, Turak EE, Öztürk ÇP, Zararsız G, Gönen ZB, Gökahmetoğlu S, Şıvgın S, Eser B, Köker Y, Solmaz M, Ünal A, Çetin M. Kaynar L, et al. Hematology. 2017 Apr;22(3):136-144. doi: 10.1080/10245332.2016.1238182. Epub 2016 Oct 10. Hematology. 2017. PMID: 27724812
-
Appelbaum FR. Appelbaum FR. Best Pract Res Clin Haematol. 2013 Sep;26(3):279-84. doi: 10.1016/j.beha.2013.10.008. Epub 2013 Oct 16. Best Pract Res Clin Haematol. 2013. PMID: 24309531 Review.
-
Ruggeri A, Ciceri F, Gluckman E, Labopin M, Rocha V; Eurocord and Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Ruggeri A, et al. Best Pract Res Clin Haematol. 2010 Jun;23(2):207-16. doi: 10.1016/j.beha.2010.06.002. Best Pract Res Clin Haematol. 2010. PMID: 20837332 Review.
Cited by
-
HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?
Ab Rahman S, Matic T, Yordanova M, Ariffin H. Ab Rahman S, et al. Front Pediatr. 2022 Jan 21;9:758680. doi: 10.3389/fped.2021.758680. eCollection 2021. Front Pediatr. 2022. PMID: 35127585 Free PMC article. Review.
-
Cellular therapies in acute lymphoblastic leukemia.
Brentjens RJ. Brentjens RJ. Curr Opin Mol Ther. 2009 Aug;11(4):375-82. Curr Opin Mol Ther. 2009. PMID: 19649982 Free PMC article. Review.
-
Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, Ciceri F, Giebel S, Gorin NC, Savani BN, Schmid C, Nagler A. Baron F, et al. Haematologica. 2017 Feb;102(2):224-234. doi: 10.3324/haematol.2016.148510. Epub 2016 Dec 7. Haematologica. 2017. PMID: 27927772 Free PMC article. Review.
-
Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, Huang H, Karakasis D, Koc Y, Michallet M, Picardi A, Sanz J, Santarone S, Sengelov H, Sierra J, Vincent L, Volt F, Nagler A, Gluckman E, Ciceri F, Rocha V, Mohty M; Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology working party-EBMT; ALWP-EBMT study. Ruggeri A, et al. Leukemia. 2015 Sep;29(9):1891-900. doi: 10.1038/leu.2015.98. Epub 2015 Apr 17. Leukemia. 2015. PMID: 25882700
-
Who is fit for allogeneic transplantation?
Deeg HJ, Sandmaier BM. Deeg HJ, et al. Blood. 2010 Dec 2;116(23):4762-70. doi: 10.1182/blood-2010-07-259358. Epub 2010 Aug 11. Blood. 2010. PMID: 20702782 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical